← All trials
NCT05457959
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2023
- Primary completion
- May 13, 2029
- Completion date
- May 13, 2030
- First posted
- Jul 14, 2022
- Last posted
- Oct 17, 2022
- Enrollment
- 15
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, Los AngelesLead sponsor
- University of California, Los AngelesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.